Xenetic Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XBIO research report →
Companywww.xeneticbio.com
Xenetic Biosciences, Inc. , a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics.
- CEO
- James F. Parslow
- IPO
- 2016
- Employees
- 2
- HQ
- Framingham, MA, US
Price Chart
Valuation
- Market Cap
- $5.35M
- P/E
- -2.91
- P/S
- 1.68
- P/B
- 0.93
- EV/EBITDA
- 0.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.71%
- Op Margin
- -75.05%
- Net Margin
- -70.03%
- ROE
- -39.28%
- ROIC
- -34.45%
Growth & Income
- Revenue
- $2.98M · 19.04%
- Net Income
- $-2,680,860 · 32.31%
- EPS
- $-1.58 · 38.52%
- Op Income
- $-2,834,582
- FCF YoY
- 18.84%
Performance & Tape
- 52W High
- $13.93
- 52W Low
- $1.90
- 50D MA
- $3.05
- 200D MA
- $2.93
- Beta
- 2.22
- Avg Volume
- 19.00K
Get TickerSpark's AI analysis on XBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 26 | PARSLOW JAMES F | other | 100,000 |
| Dec 31, 25 | VINOGRADOV ALEXEY ANDREEVICH | other | 2,500 |
| Dec 31, 25 | Dastoor Firdaus J. | other | 2,500 |
| Dec 31, 25 | Kornberg Roger D. | other | 2,500 |
| Dec 31, 25 | Borisenko Grigory G. | other | 2,500 |
| Dec 11, 24 | Kornberg Roger D. | other | 2,500 |
| Dec 11, 24 | Borisenko Grigory G. | other | 2,500 |
| Dec 11, 24 | Dastoor Firdaus J. | other | 2,500 |
| Dec 11, 24 | VINOGRADOV ALEXEY ANDREEVICH | other | 2,500 |
| Jun 18, 24 | PARSLOW JAMES F | other | 20,000 |
Our XBIO Coverage
We haven't published any research on XBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XBIO Report →